McCORMICK & COMPANY, INCORPORATED
$18.04B- Market cap
- $14.01B
- Debt
- +$4.12B
- Cash
- −$95.90M
Capital structure 77% equity / 23% debt · EV / Revenue 2.64x · EV / EBITDA 11.30x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MKC stock price vs ROIV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Needs ROIV P/E.
Implied fair value · at MKC's multiple
Needs EPS (TTM) is negative, MKC P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: MKC FY 2025 (ended Nov 30, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 77% equity / 23% debt · EV / Revenue 2.64x · EV / EBITDA 11.30x
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
ROIV carries the larger enterprise value at $21.35B against $18.04B; MKC trades on the lower EV / Revenue multiple (2.64x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
McCORMICK & COMPANY, INCORPORATED · implied price per share
Bear
$19.17
Base
$25.77
Bull
$34.68
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.72x
0.09x
Net debt / EBITDA
Leverage against operating earnings
2.52x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$95.90M
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
GENERAL MILLS INC
MKC vs GIS
HORMEL FOODS CORP /DE/
MKC vs HRL
CONAGRA BRANDS INC.
MKC vs CAG
Kraft Heinz Co
MKC vs KHC
CAMPBELL'S Co
MKC vs CPB
J M SMUCKER Co
MKC vs SJM
Mondelez International, Inc.
MKC vs MDLZ
Revolution Medicines, Inc.
MKC vs RVMD
INCYTE CORP
MKC vs INCY
Sarepta Therapeutics, Inc.
MKC vs SRPT
EXELIXIS, INC.
MKC vs EXEL
VERTEX PHARMACEUTICALS INC / MA
MKC vs VRTX
$4.12B
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.